EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: EFFICACY, SAFETY AND RENAL FUNCTION OUTCOME FROM THE TRANSFORM STUDY

被引：0
|
作者：
Sommerer, C. [1 ]
Arns, W. [1 ]
Weithofer, P. [1 ]
Lehner, F. [1 ]
Banas, B. [1 ]
van der Giet, M. [1 ]
Habicht, A. [1 ]
Renders, L. [1 ]
Rath, T. [1 ]
Bartels, M. [1 ]
Pratschke, J. [1 ]
Hessel, K. [2 ]
Bernhardt, P. [3 ]
Witzke, O. [1 ]
机构：
[1] TRANSFORM Study Grp, Heidelberg, Germany
[2] Novartis Pharma GmbH, Nurnberg, Germany
[3] Novartis Pharma GmbH, Basel, Switzerland
来源：
TRANSPLANT INTERNATIONAL | 2018年 / 31卷
关键词：
D O I：
暂无
中图分类号：
R61 [外科手术学];
学科分类号：
摘要：
PV04
引用
收藏
页码：18 / 19
页数：2
相关论文
共 50 条
  • [1] Everolimus with Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplant Recipients: Efficacy and Safety Outcomes from the TRANSFORM Study.
    Chadban, S.
    Mulgaonkar, S.
    Pascual, J.
    Tedesco, H.
    Berger, S.
    Qazi, Y.
    Legendre, C.
    Basic-Jukic, N.
    Bernhardt, P.
    Vincenti, F.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 475 - 475
  • [2] Efficacy and Safety of Everolimus with Reduced-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Results from the TRANSFORM Study
    Pascual, Julio
    Chadban, Steve
    Tedesco, Helio
    Berger, Stefan
    Qazi, Yasir
    Cruzado, Josep M.
    Bernhardt, Peter
    Legendre, Christophe
    Kim, Myoung Soo
    Vincenti, Flavio
    TRANSPLANTATION, 2018, 102 : S367 - S368
  • [3] THE TRANSFORM STUDY: 12-MONTH EFFICACY AND SAFETY OF EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Pascual, Julio
    Berger, Stefan
    Witzke, Oliver
    Chadban, Steve
    Oppenheimer, Federico
    Oberbauer, Rainer
    Watarai, Yoshihiko
    Legendre, Christophe
    Luo, Wen-Lin
    Marti, Anamaria
    Bernhardt, Peter
    Tedesco, Helio
    TRANSPLANT INTERNATIONAL, 2017, 30 : 159 - 159
  • [4] EVEROLIMUS WITH REDUCED CALCINEURIN INHIBITOR EXPOSURE IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS: INFECTION AND WOUND HEALING OUTCOMES FROM THE TRANSFORM STUDY
    Witzke, O.
    Arns, W.
    Weithofer, P.
    Lehner, F.
    Banas, B.
    van der Giet, M.
    Habicht, A.
    Renders, L.
    Rath, T.
    Bartels, M.
    Pratschke, J.
    Hessel, K.
    Bernhardt, P.
    Sommerer, C.
    TRANSPLANT INTERNATIONAL, 2018, 31 : 18 - 18
  • [5] THE TRANSFORM STUDY: EFFECT OF EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR ON 12-MONTH RENAL FUNCTION OUTCOMES IN DE NOVO KIDNEY TRANSPLANT RECIPIENTS
    Oppenheimer, Federico
    Witzke, Oliver
    Viklicky, Ondrej
    Cassuto, Elisabeth
    De Fijter, Johan
    Huynh-Do, Uyen
    Russ, Graeme
    Srinivas, Titte
    Luo, Wen-Lin
    Bernhardt, Peter
    Qazi, Yasir
    TRANSPLANT INTERNATIONAL, 2017, 30 : 162 - 162
  • [6] Renal Function Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus with Reduced-Exposure Calcineurin Inhibitor versus Mycophenolate with Standard-Exposure Calcineurin Inhibitor: Results from the TRANSFORM Study
    Oppenheimer, Federico
    Russ, Graeme
    Viklicky, Ondrej
    Oberbauer, Rainer
    Garcia, Valter
    Witzke, Oliver
    Kuypers, Dirk
    Danguilan, Romina
    Das Gupta, Ayan
    Bernhardt, Peter
    Sommerer, Claudia
    TRANSPLANTATION, 2018, 102 : S363 - S363
  • [7] Safety of Everolimus With Reduced Calcineurin Inhibitor Exposure in De Novo Kidney Transplants: An Analysis From the Randomized TRANSFORM Study
    Tedesco-Silva, Helio
    Pascual, Julio
    Viklicky, Ondrej
    Basic-Jukic, Nikolina
    Cassuto, Elisabeth
    Kim, Dean Y.
    Cruzado, Josep M.
    Sommerer, Claudia
    Bakr, Mohamed Adel
    Garcia, Valter D.
    Huynh-Do Uyen
    Russ, Graeme
    Kim, Myoung Soo
    Kuypers, Dirk
    Buchler, Matthias
    Citterio, Franco
    Gutierrez, Maria Pilar Hernandez
    Bernhardt, Peter
    Chadban, Steve
    Maldonado, Rafael
    Massari, Pablo
    Aleman, Silvina
    Maurich, Silvia
    Gaite, Luis E.
    Raffaele, Pablo
    Imperiali, Nora
    Campbell, Scott
    Hughes, Peter
    Irish, Ashley
    Kanellis, John
    Lim, Wai
    O'Connell, Philip J.
    Endre, Zoltan
    Mount, Peter
    Hengster, Paul
    Neudorfer, Peter
    Oberbauer, Rainer
    Pratschke, Johann
    Bosmans, Jean-Louis
    Broeders, Emine N.
    Weekers, Laurent
    Silva Jr, Helio Tedesco
    Neto, Elias D.
    Dimitrov, Emil P.
    Kompatzki, Alvaro
    Benavides, Carlos
    Schweineberg, Johanna
    Knotek, Mladen
    Racki, Sanjin
    Legendre, Christophe
    TRANSPLANTATION, 2019, 103 (09) : 1953 - 1963
  • [8] Everolimus with Reduced-Dose Calcineurin Inhibitor versus Mycophenolate with Standard-Dose Calcineurin Inhibitor in De Novo Kidney Transplant Recipients: Renal Function Results from the TRANSFORM Study.
    Oppenheimer, F.
    Legendre, C.
    Cruzado, J.
    Russ, G.
    Viklicky, O.
    Oberbauer, R.
    Garcia, V.
    Witzke, O.
    Kuypers, D.
    Danguilan, R.
    Bernhardt, P.
    Sommerer, C.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 258 - 258
  • [9] Effect of Everolimus with Reduced Calcineurin Inhibitor on Efficacy and Safety in De Novo Kidney Transplant Recipients: 12-Month Results from the US Cohort of TRANSFORM Study.
    Mulgaonkar, S.
    Qazi, Y.
    Kim, D.
    Peddi, V.
    McCague, K.
    Patel, D.
    Wiseman, A.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2018, 18 : 259 - 259
  • [10] EFFECT OF DONOR AGE ON EFFICACY AND SAFETY OF DE NOVO RENAL TRANSPLANT RECIPIENTS RECEIVING EVEROLIMUS WITH REDUCED-EXPOSURE CALCINEURIN INHIBITOR REGIMEN: 24-MONTH RESULTS FROM THE TRANSFORM STUDY
    Pascual, Julio
    Legendre, Christophe
    Vincenti, Flavio
    Tedesco, Helio
    Witzke, Oliver
    Viklicky, Ondrej
    Cruzado, Josep M.
    Hernandez, Maria-Pilar
    Narvekar, Prachiti
    Bernhardt, Peter
    Kuypers, Dirk
    TRANSPLANT INTERNATIONAL, 2019, 32 : 79 - 79
12345